nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—Captopril—systemic scleroderma	0.128	0.261	CbGbCtD
Gliclazide—ALB—Mycophenolate mofetil—systemic scleroderma	0.101	0.206	CbGbCtD
Gliclazide—CYP2C9—Leflunomide—systemic scleroderma	0.0879	0.179	CbGbCtD
Gliclazide—ALB—Prednisone—systemic scleroderma	0.0806	0.164	CbGbCtD
Gliclazide—CYP2C19—Prednisone—systemic scleroderma	0.0522	0.107	CbGbCtD
Gliclazide—ALB—Methotrexate—systemic scleroderma	0.0404	0.0825	CbGbCtD
Gliclazide—CYP2C9—cardial valve—systemic scleroderma	0.0131	0.565	CbGeAlD
Gliclazide—VEGFA—Enalapril—Captopril—systemic scleroderma	0.00594	0.633	CbGdCrCtD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—FBN1—systemic scleroderma	0.00327	0.0453	CbGpPWpGaD
Gliclazide—VEGFA—Glypican 1 network—BLK—systemic scleroderma	0.00288	0.0398	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—TGFBI—systemic scleroderma	0.00287	0.0397	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—CSF1—systemic scleroderma	0.00266	0.0368	CbGpPWpGaD
Gliclazide—VEGFA—smooth muscle tissue—systemic scleroderma	0.00243	0.105	CbGeAlD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—FBN1—systemic scleroderma	0.00232	0.0321	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.0023	0.0318	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—CSF1—systemic scleroderma	0.0023	0.0318	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—COL1A2—systemic scleroderma	0.00229	0.0317	CbGpPWpGaD
Gliclazide—VEGFA—Hypertrophy Model—IL1A—systemic scleroderma	0.00227	0.0315	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—TGFBI—systemic scleroderma	0.00204	0.0282	CbGpPWpGaD
Gliclazide—VEGFA—Enalapril—Lisinopril—systemic scleroderma	0.00196	0.209	CbGdCrCtD
Gliclazide—VEGFA—Integrins in angiogenesis—CSF1—systemic scleroderma	0.00185	0.0256	CbGpPWpGaD
Gliclazide—VEGFA—tendon—systemic scleroderma	0.00183	0.079	CbGeAlD
Gliclazide—VEGFA—Integrins in angiogenesis—COL1A2—systemic scleroderma	0.00169	0.0233	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—COL1A2—systemic scleroderma	0.00163	0.0225	CbGpPWpGaD
Gliclazide—VEGFA—lung—systemic scleroderma	0.0016	0.0693	CbGeAlD
Gliclazide—ABCC8—smooth muscle tissue—systemic scleroderma	0.0016	0.0693	CbGeAlD
Gliclazide—VEGFA—Platelet degranulation—SELP—systemic scleroderma	0.00158	0.0219	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.00151	0.0209	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—MMP1—systemic scleroderma	0.00135	0.0187	CbGpPWpGaD
Gliclazide—KCNJ11—tendon—systemic scleroderma	0.00131	0.0565	CbGeAlD
Gliclazide—VEGFA—Angiogenesis—NOS3—systemic scleroderma	0.0012	0.0167	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL13—systemic scleroderma	0.0012	0.0167	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00115	0.0159	CbGpPWpGaD
Gliclazide—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	0.00108	0.0149	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00107	0.0148	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR1 specific signals—NOS3—systemic scleroderma	0.00104	0.0143	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CTLA4—systemic scleroderma	0.000969	0.0134	CbGpPWpGaD
Gliclazide—VEGFA—Angiogenesis—MMP9—systemic scleroderma	0.000966	0.0134	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.00088	0.0122	CbGpPWpGaD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.00084	0.0116	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000798	0.011	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL1A—systemic scleroderma	0.000758	0.0105	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CD40LG—systemic scleroderma	0.000753	0.0104	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000749	0.0104	CbGpPWpGaD
Gliclazide—VEGFA—Glypican 1 network—TGFB1—systemic scleroderma	0.000747	0.0103	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—RHOB—systemic scleroderma	0.00074	0.0102	CbGpPWpGaD
Gliclazide—CYP2C19—digestive system—systemic scleroderma	0.00073	0.0315	CbGeAlD
Gliclazide—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000716	0.00991	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000702	0.00971	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000699	0.00967	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—COL1A2—systemic scleroderma	0.000698	0.00965	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000655	0.00907	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—ITGAM—systemic scleroderma	0.000633	0.00876	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—CSF1—systemic scleroderma	0.000629	0.0087	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000609	0.00842	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000597	0.00826	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—NOS3—systemic scleroderma	0.000595	0.00822	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—BLK—systemic scleroderma	0.000586	0.00811	CbGpPWpGaD
Gliclazide—CYP2C9—digestive system—systemic scleroderma	0.000566	0.0244	CbGeAlD
Gliclazide—ALB—Platelet degranulation—SELP—systemic scleroderma	0.000559	0.00773	CbGpPWpGaD
Gliclazide—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000538	0.00745	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000532	0.00736	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000524	0.00724	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—RHOB—systemic scleroderma	0.000483	0.00668	CbGpPWpGaD
Gliclazide—VEGFA—Dexamethasone—Mometasone—systemic scleroderma	0.000481	0.0512	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Mometasone—systemic scleroderma	0.000481	0.0512	CbGdCrCtD
Gliclazide—VEGFA—Differentiation Pathway—TGFB1—systemic scleroderma	0.000457	0.00633	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—MMP9—systemic scleroderma	0.000441	0.0061	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.00044	0.00608	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP2—systemic scleroderma	0.000431	0.00597	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL1B—systemic scleroderma	0.000395	0.00547	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000381	0.00528	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000364	0.00504	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—TGFB1—systemic scleroderma	0.000363	0.00503	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SELP—systemic scleroderma	0.000362	0.00501	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—RHOB—systemic scleroderma	0.000344	0.00476	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—NOS3—systemic scleroderma	0.000344	0.00476	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—RHOB—systemic scleroderma	0.000338	0.00467	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP9—systemic scleroderma	0.000324	0.00448	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—CSK—systemic scleroderma	0.000308	0.00426	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—TGFB1—systemic scleroderma	0.000307	0.00425	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—TGFB1—systemic scleroderma	0.000304	0.0042	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	0.00029	0.00401	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ITGAM—systemic scleroderma	0.000289	0.004	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL1A—systemic scleroderma	0.000289	0.00399	CbGpPWpGaD
Gliclazide—VEGFA—Dexamethasone—Prednisone—systemic scleroderma	0.000262	0.0279	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisone—systemic scleroderma	0.000262	0.0279	CbGdCrCtD
Gliclazide—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000261	0.00361	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000248	0.00343	CbGpPWpGaD
Gliclazide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000246	0.000606	CcSEcCtD
Gliclazide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000245	0.000605	CcSEcCtD
Gliclazide—Tachycardia—Lisinopril—systemic scleroderma	0.000245	0.000604	CcSEcCtD
Gliclazide—Abdominal pain—Azathioprine—systemic scleroderma	0.000244	0.000603	CcSEcCtD
Gliclazide—Body temperature increased—Azathioprine—systemic scleroderma	0.000244	0.000603	CcSEcCtD
Gliclazide—Skin disorder—Lisinopril—systemic scleroderma	0.000244	0.000601	CcSEcCtD
Gliclazide—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000243	0.000599	CcSEcCtD
Gliclazide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000242	0.000598	CcSEcCtD
Gliclazide—Diarrhoea—Captopril—systemic scleroderma	0.000242	0.000598	CcSEcCtD
Gliclazide—Erectile dysfunction—Prednisone—systemic scleroderma	0.000241	0.000595	CcSEcCtD
Gliclazide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000595	CcSEcCtD
Gliclazide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000241	0.000594	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00024	0.000593	CcSEcCtD
Gliclazide—Fatigue—Mycophenolic acid—systemic scleroderma	0.00024	0.000593	CcSEcCtD
Gliclazide—Nausea—Mometasone—systemic scleroderma	0.000239	0.000591	CcSEcCtD
Gliclazide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000239	0.000589	CcSEcCtD
Gliclazide—Weight increased—Prednisone—systemic scleroderma	0.000238	0.000588	CcSEcCtD
Gliclazide—Pain—Mycophenolic acid—systemic scleroderma	0.000238	0.000588	CcSEcCtD
Gliclazide—Constipation—Mycophenolic acid—systemic scleroderma	0.000238	0.000588	CcSEcCtD
Gliclazide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000587	CcSEcCtD
Gliclazide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000237	0.000584	CcSEcCtD
Gliclazide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000236	0.000583	CcSEcCtD
Gliclazide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000235	0.00058	CcSEcCtD
Gliclazide—Hypotension—Lisinopril—systemic scleroderma	0.000234	0.000578	CcSEcCtD
Gliclazide—Dizziness—Captopril—systemic scleroderma	0.000234	0.000578	CcSEcCtD
Gliclazide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000233	0.000576	CcSEcCtD
Gliclazide—Depression—Prednisone—systemic scleroderma	0.000233	0.000575	CcSEcCtD
Gliclazide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000232	0.000574	CcSEcCtD
Gliclazide—Urticaria—Leflunomide—systemic scleroderma	0.000232	0.000572	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000231	0.0032	CbGpPWpGaD
Gliclazide—Abdominal pain—Leflunomide—systemic scleroderma	0.000231	0.000569	CcSEcCtD
Gliclazide—Body temperature increased—Leflunomide—systemic scleroderma	0.000231	0.000569	CcSEcCtD
Gliclazide—Acute coronary syndrome—Prednisone—systemic scleroderma	0.00023	0.000568	CcSEcCtD
Gliclazide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000229	0.000566	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000229	0.00317	CbGpPWpGaD
Gliclazide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000566	CcSEcCtD
Gliclazide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000566	CcSEcCtD
Gliclazide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000566	CcSEcCtD
Gliclazide—Myocardial infarction—Prednisone—systemic scleroderma	0.000229	0.000565	CcSEcCtD
Gliclazide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000229	0.000565	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000228	0.000564	CcSEcCtD
Gliclazide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000228	0.000564	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000228	0.000563	CcSEcCtD
Gliclazide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000228	0.000562	CcSEcCtD
Gliclazide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000228	0.000562	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000228	0.000562	CcSEcCtD
Gliclazide—Insomnia—Lisinopril—systemic scleroderma	0.000227	0.00056	CcSEcCtD
Gliclazide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000559	CcSEcCtD
Gliclazide—Paraesthesia—Lisinopril—systemic scleroderma	0.000225	0.000556	CcSEcCtD
Gliclazide—Vomiting—Captopril—systemic scleroderma	0.000225	0.000556	CcSEcCtD
Gliclazide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000553	CcSEcCtD
Gliclazide—Dyspnoea—Lisinopril—systemic scleroderma	0.000224	0.000552	CcSEcCtD
Gliclazide—Rash—Captopril—systemic scleroderma	0.000223	0.000551	CcSEcCtD
Gliclazide—Dermatitis—Captopril—systemic scleroderma	0.000223	0.000551	CcSEcCtD
Gliclazide—Somnolence—Lisinopril—systemic scleroderma	0.000223	0.00055	CcSEcCtD
Gliclazide—Headache—Captopril—systemic scleroderma	0.000222	0.000548	CcSEcCtD
Gliclazide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000547	CcSEcCtD
Gliclazide—Dyspepsia—Lisinopril—systemic scleroderma	0.000221	0.000545	CcSEcCtD
Gliclazide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00022	0.000543	CcSEcCtD
Gliclazide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00022	0.000543	CcSEcCtD
Gliclazide—Asthma—Methotrexate—systemic scleroderma	0.000219	0.00054	CcSEcCtD
Gliclazide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000218	0.000539	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000217	0.000534	CcSEcCtD
Gliclazide—Fatigue—Lisinopril—systemic scleroderma	0.000216	0.000534	CcSEcCtD
Gliclazide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000532	CcSEcCtD
Gliclazide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000531	CcSEcCtD
Gliclazide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000215	0.000531	CcSEcCtD
Gliclazide—Pain—Lisinopril—systemic scleroderma	0.000214	0.000529	CcSEcCtD
Gliclazide—Constipation—Lisinopril—systemic scleroderma	0.000214	0.000529	CcSEcCtD
Gliclazide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000214	0.000529	CcSEcCtD
Gliclazide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000527	CcSEcCtD
Gliclazide—Bradycardia—Prednisone—systemic scleroderma	0.000213	0.000527	CcSEcCtD
Gliclazide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000524	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—CCL2—systemic scleroderma	0.000212	0.00294	CbGpPWpGaD
Gliclazide—Diarrhoea—Azathioprine—systemic scleroderma	0.000211	0.000522	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000211	0.00291	CbGpPWpGaD
Gliclazide—Nausea—Captopril—systemic scleroderma	0.00021	0.000519	CcSEcCtD
Gliclazide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00021	0.000518	CcSEcCtD
Gliclazide—Asthenia—Leflunomide—systemic scleroderma	0.000209	0.000517	CcSEcCtD
Gliclazide—Pancytopenia—Methotrexate—systemic scleroderma	0.000208	0.000513	CcSEcCtD
Gliclazide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000207	0.00051	CcSEcCtD
Gliclazide—Pruritus—Leflunomide—systemic scleroderma	0.000206	0.00051	CcSEcCtD
Gliclazide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000205	0.000507	CcSEcCtD
Gliclazide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000205	0.000506	CcSEcCtD
Gliclazide—Dizziness—Azathioprine—systemic scleroderma	0.000204	0.000504	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000203	0.000502	CcSEcCtD
Gliclazide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000202	0.000498	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000494	CcSEcCtD
Gliclazide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.0002	0.000493	CcSEcCtD
Gliclazide—Asthenia—Mycophenolic acid—systemic scleroderma	0.0002	0.000493	CcSEcCtD
Gliclazide—Diarrhoea—Leflunomide—systemic scleroderma	0.0002	0.000493	CcSEcCtD
Gliclazide—Urticaria—Lisinopril—systemic scleroderma	0.000199	0.000492	CcSEcCtD
Gliclazide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000199	0.000491	CcSEcCtD
Gliclazide—Body temperature increased—Lisinopril—systemic scleroderma	0.000198	0.000489	CcSEcCtD
Gliclazide—Abdominal pain—Lisinopril—systemic scleroderma	0.000198	0.000489	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000198	0.00274	CbGpPWpGaD
Gliclazide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000197	0.000487	CcSEcCtD
Gliclazide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000197	0.000486	CcSEcCtD
Gliclazide—Vomiting—Azathioprine—systemic scleroderma	0.000197	0.000485	CcSEcCtD
Gliclazide—Pneumonia—Methotrexate—systemic scleroderma	0.000196	0.000485	CcSEcCtD
Gliclazide—Eye disorder—Prednisone—systemic scleroderma	0.000196	0.000484	CcSEcCtD
Gliclazide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000196	0.000484	CcSEcCtD
Gliclazide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000482	CcSEcCtD
Gliclazide—Drowsiness—Methotrexate—systemic scleroderma	0.000195	0.000482	CcSEcCtD
Gliclazide—Rash—Azathioprine—systemic scleroderma	0.000195	0.000481	CcSEcCtD
Gliclazide—Dermatitis—Azathioprine—systemic scleroderma	0.000195	0.000481	CcSEcCtD
Gliclazide—Depression—Methotrexate—systemic scleroderma	0.000195	0.00048	CcSEcCtD
Gliclazide—Flushing—Prednisone—systemic scleroderma	0.000195	0.00048	CcSEcCtD
Gliclazide—Headache—Azathioprine—systemic scleroderma	0.000194	0.000478	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000193	0.000478	CcSEcCtD
Gliclazide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000477	CcSEcCtD
Gliclazide—Dizziness—Leflunomide—systemic scleroderma	0.000193	0.000476	CcSEcCtD
Gliclazide—Renal failure—Methotrexate—systemic scleroderma	0.000192	0.000474	CcSEcCtD
Gliclazide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000191	0.00047	CcSEcCtD
Gliclazide—Conjunctivitis—Methotrexate—systemic scleroderma	0.00019	0.000468	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00019	0.000468	CcSEcCtD
Gliclazide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000464	CcSEcCtD
Gliclazide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000464	CcSEcCtD
Gliclazide—Arrhythmia—Prednisone—systemic scleroderma	0.000187	0.000462	CcSEcCtD
Gliclazide—Sweating—Methotrexate—systemic scleroderma	0.000187	0.000462	CcSEcCtD
Gliclazide—Vomiting—Leflunomide—systemic scleroderma	0.000186	0.000458	CcSEcCtD
Gliclazide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000185	0.000456	CcSEcCtD
Gliclazide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000185	0.000456	CcSEcCtD
Gliclazide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000184	0.000454	CcSEcCtD
Gliclazide—Epistaxis—Methotrexate—systemic scleroderma	0.000184	0.000454	CcSEcCtD
Gliclazide—Rash—Leflunomide—systemic scleroderma	0.000184	0.000454	CcSEcCtD
Gliclazide—Dermatitis—Leflunomide—systemic scleroderma	0.000184	0.000454	CcSEcCtD
Gliclazide—Mental disorder—Prednisone—systemic scleroderma	0.000184	0.000453	CcSEcCtD
Gliclazide—Nausea—Azathioprine—systemic scleroderma	0.000184	0.000453	CcSEcCtD
Gliclazide—Headache—Leflunomide—systemic scleroderma	0.000183	0.000451	CcSEcCtD
Gliclazide—Malnutrition—Prednisone—systemic scleroderma	0.000182	0.00045	CcSEcCtD
Gliclazide—Erythema—Prednisone—systemic scleroderma	0.000182	0.00045	CcSEcCtD
Gliclazide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000182	0.00045	CcSEcCtD
Gliclazide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000447	CcSEcCtD
Gliclazide—Asthenia—Lisinopril—systemic scleroderma	0.00018	0.000444	CcSEcCtD
Gliclazide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000444	CcSEcCtD
Gliclazide—Pruritus—Lisinopril—systemic scleroderma	0.000177	0.000438	CcSEcCtD
Gliclazide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000177	0.000437	CcSEcCtD
Gliclazide—Rash—Mycophenolic acid—systemic scleroderma	0.000176	0.000433	CcSEcCtD
Gliclazide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000175	0.000433	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—systemic scleroderma	0.000175	0.000432	CcSEcCtD
Gliclazide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000431	CcSEcCtD
Gliclazide—Headache—Mycophenolic acid—systemic scleroderma	0.000174	0.000431	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—systemic scleroderma	0.000174	0.000429	CcSEcCtD
Gliclazide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000429	CcSEcCtD
Gliclazide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000429	CcSEcCtD
Gliclazide—Nausea—Leflunomide—systemic scleroderma	0.000173	0.000428	CcSEcCtD
Gliclazide—Diarrhoea—Lisinopril—systemic scleroderma	0.000172	0.000424	CcSEcCtD
Gliclazide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000169	0.000418	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—systemic scleroderma	0.000169	0.000417	CcSEcCtD
Gliclazide—Anaemia—Prednisone—systemic scleroderma	0.000169	0.000416	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000169	0.00233	CbGpPWpGaD
Gliclazide—Agitation—Prednisone—systemic scleroderma	0.000168	0.000414	CcSEcCtD
Gliclazide—Angioedema—Prednisone—systemic scleroderma	0.000167	0.000412	CcSEcCtD
Gliclazide—Dizziness—Lisinopril—systemic scleroderma	0.000166	0.000409	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000166	0.000409	CcSEcCtD
Gliclazide—Nausea—Mycophenolic acid—systemic scleroderma	0.000165	0.000408	CcSEcCtD
Gliclazide—Malaise—Prednisone—systemic scleroderma	0.000165	0.000406	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—systemic scleroderma	0.000164	0.000404	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—systemic scleroderma	0.000163	0.000403	CcSEcCtD
Gliclazide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000162	0.0004	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IL1B—systemic scleroderma	0.000161	0.00223	CbGpPWpGaD
Gliclazide—Loss of consciousness—Prednisone—systemic scleroderma	0.00016	0.000396	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MMP2—systemic scleroderma	0.00016	0.00222	CbGpPWpGaD
Gliclazide—Vomiting—Lisinopril—systemic scleroderma	0.000159	0.000394	CcSEcCtD
Gliclazide—Rash—Lisinopril—systemic scleroderma	0.000158	0.00039	CcSEcCtD
Gliclazide—Convulsion—Prednisone—systemic scleroderma	0.000158	0.00039	CcSEcCtD
Gliclazide—Dermatitis—Lisinopril—systemic scleroderma	0.000158	0.00039	CcSEcCtD
Gliclazide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000389	CcSEcCtD
Gliclazide—Hypertension—Prednisone—systemic scleroderma	0.000158	0.000389	CcSEcCtD
Gliclazide—Chills—Methotrexate—systemic scleroderma	0.000157	0.000388	CcSEcCtD
Gliclazide—Headache—Lisinopril—systemic scleroderma	0.000157	0.000388	CcSEcCtD
Gliclazide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000384	CcSEcCtD
Gliclazide—Arthralgia—Prednisone—systemic scleroderma	0.000155	0.000384	CcSEcCtD
Gliclazide—Myalgia—Prednisone—systemic scleroderma	0.000155	0.000384	CcSEcCtD
Gliclazide—Anxiety—Prednisone—systemic scleroderma	0.000155	0.000382	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000154	0.000381	CcSEcCtD
Gliclazide—Discomfort—Prednisone—systemic scleroderma	0.000154	0.000379	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—systemic scleroderma	0.000153	0.000379	CcSEcCtD
Gliclazide—Erythema—Methotrexate—systemic scleroderma	0.000153	0.000376	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—systemic scleroderma	0.000153	0.000376	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000152	0.0021	CbGpPWpGaD
Gliclazide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000371	CcSEcCtD
Gliclazide—Nausea—Lisinopril—systemic scleroderma	0.000149	0.000368	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—SMAD7—systemic scleroderma	0.000148	0.00205	CbGpPWpGaD
Gliclazide—Infection—Prednisone—systemic scleroderma	0.000148	0.000365	CcSEcCtD
Gliclazide—Back pain—Methotrexate—systemic scleroderma	0.000148	0.000364	CcSEcCtD
Gliclazide—Nervous system disorder—Prednisone—systemic scleroderma	0.000146	0.000361	CcSEcCtD
Gliclazide—Tachycardia—Prednisone—systemic scleroderma	0.000145	0.000359	CcSEcCtD
Gliclazide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000359	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—MMP1—systemic scleroderma	0.000145	0.00201	CbGpPWpGaD
Gliclazide—Skin disorder—Prednisone—systemic scleroderma	0.000145	0.000357	CcSEcCtD
Gliclazide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000144	0.000355	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000142	0.000349	CcSEcCtD
Gliclazide—ABCC8—Metabolism—HSPG2—systemic scleroderma	0.000141	0.00196	CbGpPWpGaD
Gliclazide—Anaemia—Methotrexate—systemic scleroderma	0.000141	0.000348	CcSEcCtD
Gliclazide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000345	CcSEcCtD
Gliclazide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000342	CcSEcCtD
Gliclazide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000342	CcSEcCtD
Gliclazide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000138	0.00034	CcSEcCtD
Gliclazide—Malaise—Methotrexate—systemic scleroderma	0.000138	0.000339	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—HSPG2—systemic scleroderma	0.000137	0.0019	CbGpPWpGaD
Gliclazide—Leukopenia—Methotrexate—systemic scleroderma	0.000137	0.000337	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000136	0.000335	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000135	0.00187	CbGpPWpGaD
Gliclazide—Insomnia—Prednisone—systemic scleroderma	0.000135	0.000333	CcSEcCtD
Gliclazide—Paraesthesia—Prednisone—systemic scleroderma	0.000134	0.00033	CcSEcCtD
Gliclazide—Cough—Methotrexate—systemic scleroderma	0.000133	0.000329	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—systemic scleroderma	0.000132	0.000326	CcSEcCtD
Gliclazide—Dyspepsia—Prednisone—systemic scleroderma	0.000131	0.000324	CcSEcCtD
Gliclazide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000322	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—systemic scleroderma	0.00013	0.000321	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—systemic scleroderma	0.00013	0.000321	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—systemic scleroderma	0.00013	0.000321	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000129	0.000318	CcSEcCtD
Gliclazide—Fatigue—Prednisone—systemic scleroderma	0.000128	0.000317	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—systemic scleroderma	0.000128	0.000317	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000128	0.00177	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SELP—systemic scleroderma	0.000128	0.00177	CbGpPWpGaD
Gliclazide—Constipation—Prednisone—systemic scleroderma	0.000127	0.000314	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—systemic scleroderma	0.000126	0.00031	CcSEcCtD
Gliclazide—Infection—Methotrexate—systemic scleroderma	0.000124	0.000305	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisone—systemic scleroderma	0.000123	0.000303	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000122	0.000301	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000122	0.000301	CcSEcCtD
Gliclazide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000122	0.000301	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—systemic scleroderma	0.000121	0.000298	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MMP9—systemic scleroderma	0.00012	0.00167	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00012	0.000297	CcSEcCtD
Gliclazide—ALB—Hemostasis—RHOB—systemic scleroderma	0.000119	0.00165	CbGpPWpGaD
Gliclazide—Urticaria—Prednisone—systemic scleroderma	0.000118	0.000292	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—systemic scleroderma	0.000118	0.000291	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—systemic scleroderma	0.000118	0.000291	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—systemic scleroderma	0.000116	0.000287	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—RHOB—systemic scleroderma	0.000115	0.00158	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP2—systemic scleroderma	0.000114	0.00158	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000113	0.00028	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—systemic scleroderma	0.000113	0.000278	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—systemic scleroderma	0.000112	0.000276	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—systemic scleroderma	0.000111	0.000274	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—systemic scleroderma	0.000111	0.000273	CcSEcCtD
Gliclazide—Hypersensitivity—Prednisone—systemic scleroderma	0.00011	0.000271	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—systemic scleroderma	0.00011	0.00027	CcSEcCtD
Gliclazide—ALB—Hemostasis—CSK—systemic scleroderma	0.000109	0.0015	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HSPG2—systemic scleroderma	0.000108	0.00149	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000107	0.000265	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—systemic scleroderma	0.000107	0.000265	CcSEcCtD
Gliclazide—ALB—Platelet degranulation—TGFB1—systemic scleroderma	0.000107	0.00148	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CTGF—systemic scleroderma	0.000107	0.00148	CbGpPWpGaD
Gliclazide—Asthenia—Prednisone—systemic scleroderma	0.000107	0.000264	CcSEcCtD
Gliclazide—Pain—Methotrexate—systemic scleroderma	0.000106	0.000263	CcSEcCtD
Gliclazide—Pruritus—Prednisone—systemic scleroderma	0.000105	0.00026	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—NOS3—systemic scleroderma	0.000105	0.00145	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CSK—systemic scleroderma	0.000104	0.00144	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CTGF—systemic scleroderma	0.000104	0.00144	CbGpPWpGaD
Gliclazide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000103	0.000253	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000102	0.00142	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	0.000102	0.00141	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ITGAM—systemic scleroderma	0.000102	0.00141	CbGpPWpGaD
Gliclazide—Diarrhoea—Prednisone—systemic scleroderma	0.000102	0.000252	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000102	0.000251	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—systemic scleroderma	9.89e-05	0.000244	CcSEcCtD
Gliclazide—Dizziness—Prednisone—systemic scleroderma	9.85e-05	0.000243	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—systemic scleroderma	9.84e-05	0.000243	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—systemic scleroderma	9.84e-05	0.000243	CcSEcCtD
Gliclazide—Vomiting—Prednisone—systemic scleroderma	9.47e-05	0.000234	CcSEcCtD
Gliclazide—Rash—Prednisone—systemic scleroderma	9.39e-05	0.000232	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—systemic scleroderma	9.38e-05	0.000232	CcSEcCtD
Gliclazide—Headache—Prednisone—systemic scleroderma	9.33e-05	0.00023	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	9.19e-05	0.00127	CbGpPWpGaD
Gliclazide—Hypersensitivity—Methotrexate—systemic scleroderma	9.17e-05	0.000226	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—systemic scleroderma	8.93e-05	0.00022	CcSEcCtD
Gliclazide—Nausea—Prednisone—systemic scleroderma	8.85e-05	0.000218	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—systemic scleroderma	8.81e-05	0.000217	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MMP9—systemic scleroderma	8.6e-05	0.00119	CbGpPWpGaD
Gliclazide—Diarrhoea—Methotrexate—systemic scleroderma	8.52e-05	0.00021	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.38e-05	0.00116	CbGpPWpGaD
Gliclazide—Dizziness—Methotrexate—systemic scleroderma	8.23e-05	0.000203	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—systemic scleroderma	7.91e-05	0.000195	CcSEcCtD
Gliclazide—Rash—Methotrexate—systemic scleroderma	7.85e-05	0.000194	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—systemic scleroderma	7.84e-05	0.000194	CcSEcCtD
Gliclazide—Headache—Methotrexate—systemic scleroderma	7.8e-05	0.000192	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.76e-05	0.00107	CbGpPWpGaD
Gliclazide—Nausea—Methotrexate—systemic scleroderma	7.39e-05	0.000183	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—TGFB1—systemic scleroderma	7.09e-05	0.00098	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.96e-05	0.000963	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—systemic scleroderma	6.95e-05	0.000961	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.35e-05	0.000878	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EDN1—systemic scleroderma	5.85e-05	0.000809	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MMP1—systemic scleroderma	5.12e-05	0.000708	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.76e-05	0.000658	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NOS3—systemic scleroderma	4.66e-05	0.000645	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HSPG2—systemic scleroderma	4.56e-05	0.000631	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NOS3—systemic scleroderma	4.52e-05	0.000626	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HSPG2—systemic scleroderma	4.09e-05	0.000566	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—systemic scleroderma	4e-05	0.000553	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HSPG2—systemic scleroderma	3.73e-05	0.000516	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—systemic scleroderma	3.71e-05	0.000513	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—systemic scleroderma	3.56e-05	0.000493	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CTGF—systemic scleroderma	3.46e-05	0.000478	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CTGF—systemic scleroderma	3.1e-05	0.000429	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—systemic scleroderma	2.86e-05	0.000395	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CTGF—systemic scleroderma	2.83e-05	0.000391	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—systemic scleroderma	2.45e-05	0.000339	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—systemic scleroderma	2.36e-05	0.000326	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—systemic scleroderma	1.5e-05	0.000208	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—systemic scleroderma	1.35e-05	0.000187	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.23e-05	0.00017	CbGpPWpGaD
